抄録
No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
本文言語 | 英語 |
---|---|
ページ(範囲) | 89-94 |
ページ数 | 6 |
ジャーナル | Acta Medica Okayama |
巻 | 74 |
号 | 1 |
出版ステータス | 出版済み - 2020 |
外部発表 | はい |
All Science Journal Classification (ASJC) codes
- 生化学、遺伝学、分子生物学一般